About Us
Cimeio Therapeutics
We are an applied gene editing, cellular, and immunotherapy company developing a portfolio of Shielded-Cell & Immunotherapy Pairs™ for patients with debilitating and life-threatening diseases. Our proprietary technology platform is based on the discovery of novel protein variants, which when inserted into cells allow them to preserve function while resisting depletion by a precisely paired immunotherapy. This technology has significant therapeutic potential, which we are using to develop curative treatments for patients with genetic diseases, hematologic malignancies, and severe autoimmune disorders.
Leadership
Thomas Fuchs
Chief Executive Officer
Tristan Imbert
Chief Financial Officer
Lukas Jeker, MD/PhD
Founder, SVP Gene Editing
Daniel Stark, PhD
Chief Manufacturing Officer
Stefanie Urlinger, PhD
SVP Biology
Thomas Winkler, MD
Chief Medical Officer
Thomas Fuchs
Chief Executive Officer
Tristan Imbert
Chief Financial Officer
Lukas Jeker, MD/PhD
SVP Gene Editing
Daniel Stark, PhD
Chief Manufacturing Officer
Stefanie Urlinger, PhD
SVP Biology
Thomas Winkler, MD
Chief Medical Officer
Scientific Advisory Board
Suneet Agarwal, MD, PhD
Assoc. Prof. Harvard Medical School
Jeff Bluestone, PhD
CEO, Sonoma Bio
Toni Cathomen, MD
Prof. University of Freiburg
Corey Cutler, MD, MPH, FRCPC
Assoc. Prof. Harvard Medical School
Fyodor Urnov, PhD, Chair
Prof. University of California Berkeley
Suneet Agarwal, MD, PhD
Jeff Bluestone, PhD
Toni Cathomen, MD
Corey Cutler, MD, MPH, FRCPC
Fyodor Urnov, PhD, Chair
Board of Directors
Lukas Jeker, MD/PhD
Founder, SVP Gene Editing
Markus Enzelberger, Ph.D.
Partner at Versant Ventures
Alexander Mayweg, Ph.D.
President of Ridgeline Discovery and Managing Director at Versant Ventures
Team
Marc Bigler
Thomas Burgold
Anna Camus
Valentin Do Sacramento
Laura Garcia Prat
Eva-Maria Grossjohann
Tanja Herrmann
Marcel Heugel
Andreja Knezevic
Mariah Kohlbrenner
Frank Lehmann
Emiel Ten Buren
Saniye Yumlu
